Brain+ Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Kim Baden-Kristensen

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	0.3%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	1.1yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Kim Baden-Kristensen

no data

Titularisation

Mr. Kim Baden-Kristensen is Co-Founder, Chief Executive Officer and Managing Director of Brain+ ApS. He is Co-Founder and Chief Executive Officer, MD & Member of Executive board of Brain+ A/S. He began his...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Derk Krieger	Chairman of Advisory Board	no data	pas de données	pas de données
Per Luthman	Director	2.2yrs	pas de données	pas de données
Anish Chouksey	Director	1.1yrs	pas de données	pas de données
Tim Juergens	Chairman	less than a year	pas de données	pas de données

1.1yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la BRAINP n'est pas considéré comme expérimenté ( 1.1 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Brain+ Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Brain+ A/S Announces the Appointment of Devika Rani Wood as Chief Commercial Officer, Effective August 14, 2024

Brain+ A/S Announces Election of Tim Juergens as New Board Member and Chairman

Brain+ A/S, Annual General Meeting, May 15, 2024

Brain+ A/S Announces CFO Changes

Brain+ A/S Announces Resignation of Anders Härfstrand as Chairman and Member of the Board, Effective from January 31, 2024

Brain+ A/S Announces Resignation of Betül Susamis Unaran, Member of the Board of Directors, Effective on 30 November

Recent updates

Brain+ A/S Launches Ayla - your CST Assistant into the UK Dementia Market

Brain+ A/S Confirms Imminent Commercial Launch of Ayla - Your CST Assistant as a Medical Device in the UK

Brain+ A/S Informs of Three Product Releases Planned for 2025 and Introduces A Platform Renaming as Part of Its UK Commercialization

First Patient Enters in A Clinical Trial to Evaluate Brain+' Next Generation Cognitive Training Technology for Mild Cognitive Impairment

Brain+ A/S Announces Results from UK Study of the CST Assistant Show Clinical Relevance, Cost-Benefits and Product-Market Fit

Brain+ A/S Announces Clinical Evaluation Report of the CST- Assistant Has Now Been Valued for UK Regulatory Compliance

The Cst Assistant V2.0 for Cognitive Stimulation Therapy (Cst) Now Released in Denmark

Brain+ A/S Announces the Appointment of Devika Rani Wood as Chief Commercial Officer, Effective August 14, 2024

Brain+ Announces The CST-Assistant v2.0 is Now Ready for Release in Denmark and on Track for Release in the UK End of Third Quarter of 2024

Brain+ A/S Announces Election of Tim Juergens as New Board Member and Chairman

Brain+ A/S Provides Earnings Guidance for the Year 2024

Brain+ A/S to Report Fiscal Year 2023 Results on Apr 30, 2024

Brain+ A/S, Annual General Meeting, May 15, 2024

Brain+ A/S Announces CFO Changes

Brain+ A/S Announces Resignation of Anders Härfstrand as Chairman and Member of the Board, Effective from January 31, 2024

Brain+ Nominates to CO-PI Grant of Up to DKK 3.5 Million from Denmark's Business Promotion Board

Brain+ A/S Announces Resignation of Betül Susamis Unaran, Member of the Board of Directors, Effective on 30 November

Brain+ A/S Releases New Version of Its Cst-Therapist Companion Dementia Product with Updated User Features

Brain+ Secures Intellectual Property Rights for CST-Therapist Companion in the Eu and the United Kingdom

Brain+ A/S Provides Earnings Guidance for the Full Year 2023

Brain+ A/S Announces Breakthrough Alzheimer's Drug Approval Seen to Renew Dementia Drug Investments and Increase the Potential for Digital Dementia Therapeutics

No independent directors

Brain+ A/S Announces Board Resignation

Brain+ A/S Completes Swedish Research Version of Its Dementia Product with the Research Institutes of Sweden and Extends the Collaboration

Brain+ A/S Announces Results from Clinical Study Provide Promising Feasibility Indications for Brain+' CCT Technology for Cognitive Training

Brain+ A/S Announces 3-Year Innovation Project with the Danish Life Science Cluster Is Completed with the Brain+ CST-Therapist Companion Product as the Final Output

Less than half of directors are independent

Brain+ Announces Board Appointments

Brain+ Announces Its First Digital Dementia Product, Cognitive Stimulation Therapy (CST)-Therapist Companion

Less than half of directors are independent

Brain+ A/S Approves Board Changes

Brain+' New Digital Product for Dementia, “CST-Therapist Companion” Is Ready for Commercial Launch in Denmark

Brain+ A/S Announces Retirement of Jonas Nilsen from the Board

Kim Arvid Nielsen Decides to Step Down from the Board of Brain+ A/S

Paula Petcu Joins Brain+ as New Chief Technology Officer

Brain+ A/S Announces Publication of Results from an Earlier Study That Showed Cognitive Improvements in People with Brain Injury After Training with Brain+ Recover Computerized Cognitive Training Product

Positive Results from the First of Four Clinical Studies to Evaluate Brain+' Starry Night Cognitive Test for Early Detection of Alzheimer's Disease

Brain+ A/S Appoints Bertil S. Jessen as Chief Financial Officer, Effective March 1, 2022

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi